CPSP 2016 Results
The Canadian Paediatric Surveillance Program's 2016 Results are now available. The publication includes nine studies, as well as results from four one-time surveys. Read the report online, or email us at email@example.com to request a paper copy. Sincere thanks to all members who participated in the program in 2016.
New study on Infantile and later-onset paediatric Pompe disease
On October 1, the Canadian Paediatric Surveillance Program (CPSP) began a new study on Infantile and later-onset paediatric Pompe disease (PD), also known as glycogen storage disease type II (GSD-II). Pompe disease is an inherited, autosomal recessive disease that results from abnormal lysosomal storage of glycogen in body tissues. Early diagnosis is particularly important given that early treatment has shown to improve cardiomyopathy, ventilator function, and prolong survival in patients with infantile Pompe disease, and also improve muscle strength, pulmonary function, and survival in patients with later-onset Pompe disease. For more information and to report a case, refer to the protocol and case definition.
Find out timely tips on adverse drug reactions reported to the CPSP and Health Canada.
Results pertaining to studies and surveys are published annually. Click here for CPSP Results from 1999.
Electronic Reporting Option
Sign up for monthly electronic reporting today. The process is quick and simple – a hyperlink is sent to you each month and no log-in and password are required.Sign Up Now
The Canadian Paediatric Surveillance Program
The Canadian Paediatric Surveillance Program (CPSP) contributes to the improvement of the health of children and youth in Canada by national surveillance and research into childhood disorders that are high in disability, morbidity and economic costs to society, despite their low frequency. Read More.